SLDX Stock Overview
Stella Diagnostics, Inc., a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Stella Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.042 |
| 52 Week High | US$0.30 |
| 52 Week Low | US$0.027 |
| Beta | 0 |
| 11 Month Change | -20.75% |
| 3 Month Change | -17.65% |
| 1 Year Change | -58.00% |
| 33 Year Change | -94.40% |
| 5 Year Change | -68.89% |
| Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| SLDX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 0.9% |
| 1Y | -58.0% | 12.0% | 32.3% |
Return vs Industry: SLDX underperformed the US Healthcare industry which returned 12% over the past year.
Return vs Market: SLDX underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| SLDX volatility | |
|---|---|
| SLDX Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SLDX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SLDX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | David Seaburg | www.stelladx.com |
Stella Diagnostics, Inc., a molecular diagnostics-based company, focuses on enhancing patient management strategies for people living with severe esophageal diseases. Its clinical assays offer physicians insight into the molecular properties of patients’ tissue to determine if the disease is stable, progressing, or turning cancerous. The company is also developing diagnostic tools that provides molecular information for providers as compared to the screening protocols.
Stella Diagnostics Inc. Fundamentals Summary
| SLDX fundamental statistics | |
|---|---|
| Market cap | US$16.87m |
| Earnings (TTM) | -US$257.97k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs SLDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$7.50k |
| Gross Profit | -US$7.50k |
| Other Expenses | US$250.47k |
| Earnings | -US$257.97k |
Last Reported Earnings
Dec 31, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SLDX perform over the long term?
See historical performance and comparison